Search Results 1941-1950 of 20081 for Receptor

  1. Meet My Research: Ismail Can - News Archive - Mayo Clinic College of Medicine & Science

    One of the major advances in cancer treatments that we are witnessing is chimeric antigen receptor T (CART) cell therapy. CART cells are taken from cancer ...

  2. Brain Tumor Program - Clinical trials

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  3. Neurosurgery - Clinical trials

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  4. Zanzalintinib Versus Everolimus In Participants With Locally Advanced Or Metastatic Neuroendocrine Tumors - Mayo Clinic

    * Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) ...

  5. A Safety Study Of SYNT001 In Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA) - Mayo Clinic

    Cellular therapy, including chimeric antigen receptor and T-cell (CAR-T), at any time prior to screening. Use of any immunosuppressive drugs within 3 months ...

  6. Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer - Mayo Clinic

    Hormone receptor status: Positive or negative. PATIENT CHARACTERISTICS: Age: 18 and over; Sex: Female; Menopausal status: Not specified; Performance status ...

  7. A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer - Mayo Clinic

    Prior treatment with CYP17 inhibitor (e.g., ketoconazole, abiraterone acetate, galeterone) or next generation androgen receptor antagonist including apalutamide ...

  8. SYMPHONY: A Study Of Macitentan In Pulmonary Arterial Hypertension To Validate The PAH-SYMPACT - Mayo Clinic

    Treatment with endothelin receptor antagonists (ERAs) within 3 months prior to Visit 2, or scheduled to receive any of these compounds, other than macitentan, ...

  9. A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache - Mayo Clinic

    Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth ...

  10. Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab - Mayo Clinic

    Subjects with NSCLC who are known to be epidermal growth factor receptor (EGFR)-mutation positive must have received an EGFR inhibitor and subjects known to ...